The Role of β3-Integrin in Cervical Cancer Outcomes
Author Information
Author(s): Gruber G, Hess J, Stiefel C, Aebersold D M, Zimmer Y, Greiner R H, Studer U, Altermatt H J, Hlushchuk R, Djonov V
Primary Institution: Department of Radiation Oncology, University of Bern, Switzerland
Hypothesis
Does the expression of β3-integrin serve as a prognostic marker for survival in cervical cancer patients who have undergone radiotherapy?
Conclusion
The expression of β3-integrin is significantly associated with worse survival outcomes in cervical cancer patients treated with radiotherapy.
Supporting Evidence
- 61% of patients expressed β3-integrin.
- Patients with β3-integrin expression had significantly shorter local progression-free survival.
- Multivariate analysis confirmed β3-integrin positivity as an independent prognostic factor.
Takeaway
This study found that many cervical cancer patients have a protein called β3-integrin, and those with it tend to do worse after treatment.
Methodology
Biopsies from 82 cervical cancer patients were analyzed for β3-integrin expression and correlated with survival outcomes using statistical analyses.
Potential Biases
Potential biases may arise from the selection of patients and the retrospective nature of the study.
Limitations
The study was limited to a specific patient cohort and may not generalize to all cervical cancer patients.
Participant Demographics
Patients included had squamous cell or adenocarcinomas of the cervix, with a majority in advanced FIGO stages (IIb–IVa).
Statistical Information
P-Value
0.002
Confidence Interval
RR=6.81 (2.21–21.00)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website